437 related articles for article (PubMed ID: 32903405)
1. CAR T Cell Therapy for Pediatric Brain Tumors.
Patterson JD; Henson JC; Breese RO; Bielamowicz KJ; Rodriguez A
Front Oncol; 2020; 10():1582. PubMed ID: 32903405
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.
Chatterjee A; Asija S; Yadav S; Purwar R; Goda JS
Int Rev Immunol; 2022; 41(6):606-624. PubMed ID: 36191126
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Screening Assay for Activators of T-Cell Migration to Solid Tumors.
Dey A; Sharp DJ
Methods Mol Biol; 2022; 2423():109-113. PubMed ID: 34978693
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cell Therapy's Potential for Pediatric Brain Tumors.
Thomas P; Galopin N; Bonérandi E; Clémenceau B; Fougeray S; Birklé S
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771608
[TBL] [Abstract][Full Text] [Related]
5. The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues.
Burns I; Gwynne WD; Suk Y; Custers S; Chaudhry I; Venugopal C; Singh SK
Front Oncol; 2022; 12():815726. PubMed ID: 35155252
[TBL] [Abstract][Full Text] [Related]
6. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Del Baldo G; Del Bufalo F; Pinacchio C; Carai A; Quintarelli C; De Angelis B; Merli P; Cacchione A; Locatelli F; Mastronuzzi A
Front Immunol; 2023; 14():1142597. PubMed ID: 37025994
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572932
[TBL] [Abstract][Full Text] [Related]
8. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
9. Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors.
Mount CW; Gonzalez Castro LN
Antibodies (Basel); 2022 Apr; 11(2):. PubMed ID: 35645204
[TBL] [Abstract][Full Text] [Related]
10. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
11. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
12. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
13. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.
Haydar D; Ibañez-Vega J; Krenciute G
Front Oncol; 2021; 11():718030. PubMed ID: 34760690
[TBL] [Abstract][Full Text] [Related]
14. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Nellan A; Rota C; Majzner R; Lester-McCully CM; Griesinger AM; Mulcahy Levy JM; Foreman NK; Warren KE; Lee DW
J Immunother Cancer; 2018 Apr; 6(1):30. PubMed ID: 29712574
[TBL] [Abstract][Full Text] [Related]
15. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
17. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.
Xia AL; Wang XC; Lu YJ; Lu XJ; Sun B
Oncotarget; 2017 Oct; 8(52):90521-90531. PubMed ID: 29163850
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapy for glioblastoma.
Rodriguez A; Brown C; Badie B
Transl Res; 2017 Sep; 187():93-102. PubMed ID: 28755873
[TBL] [Abstract][Full Text] [Related]
19. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.
Petersen CT; Krenciute G
Front Oncol; 2019; 9():69. PubMed ID: 30863720
[TBL] [Abstract][Full Text] [Related]
20. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
